- Voxelotor
-
- $35.00
-
2026-09-02
- CAS:1446321-46-5
- Min. Order: 1kg
- Purity: 99%
- Voxelotor
-
-
2026-09-01
- CAS:1446321-46-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20tons
- voxelotor
-
- $42.00
-
2026-07-15
- CAS:1446321-46-5
- Purity: 99.90%
- Supply Ability: 10g
|
| | Voxelotor Basic information |
| Product Name: | Voxelotor | | Synonyms: | 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde;GBT 440;2-Hydroxy-6-{[2-(1-isopropyl-1H-pyrazol-5-yl)-3-pyridinyl]methoxy}benzaldehyde;Hemoglobin Modulators-1;2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde;Voxelotor(GBT440, GTX011);Voxelotor;Voxelotor, GBT-440, GBT 440, GBT440, GTx-011, GTx011, GTx 011 | | CAS: | 1446321-46-5 | | MF: | C19H19N3O3 | | MW: | 337.37 | | EINECS: | | | Product Categories: | API | | Mol File: | 1446321-46-5.mol |  |
| | Voxelotor Chemical Properties |
| Melting point | 95 - 97oC | | Boiling point | 539.2±50.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | Chloroform (Slightly), DMSO (Slightly) | | form | Solid | | pka | 7.67±0.10(Predicted) | | color | White to Off-White | | InChI | InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3 | | InChIKey | FWCVZAQENIZVMY-UHFFFAOYSA-N | | SMILES | C(=O)C1=C(OCC2=CC=CN=C2C2N(C(C)C)N=CC=2)C=CC=C1O |
| | Voxelotor Usage And Synthesis |
| Uses | GBT 440 is a potent allosteric effector of sickle cell hemoglobin (Hb) that increases the affinity of Hb for oxygen and inhibits its polymerization when subjected to hypoxic conditions. | | Biological Activity | Voxelotor improves the abnormal aggregation of hemoglobin under hypoxic conditions, which is the main cause of sickle cell disease-related red blood cell dysfunction, by forming a Schiff base with the N-terminal valine of the hemoglobin alpha chain, increasing the affinity of sickle cell hemoglobin for oxygen and preventing its aggregation. | | Synthesis | below shows the synthesis route of Voxelotor
 | | in vivo | | Animal Model: | HbSS Townes knock-in sickle mice (SS mice)[1] | | Dosage: | 100 and 150 mg/kg | | Administration: | Oral administration; twice a day; for 9-12 days | | Result: | Reduced haemolysis. |
| Animal Model: | C57BL/6J mice, Sprague-Dawley rats, Beagle dogs and Cynomolgus monkeys[1] | | Dosage: | 70, 1.6, 1 and 1 mg/kg for mice, rats, dogs and monkeys, respectively
30, 7.2, 2.5 and 4.25 mg/kg for mice, rats, dogs and monkeys, respectively | | Administration: | Intravenous (IV: 70, 1 6, 1 and 1 mg/kg, respectively)
Oral (PO: 30, 7 2, 2 5 and 4 3 mg/kg, respectively) | | Result: | T1/2s of 11.7, 19.1±1.5, 66.0±11, 28.8±4.0 hours for mouse (70 mg/kg; i.v.), rat (1.6 mg/kg; i.v.), dog (1 mg/kg; i.v.), and momkey (1 mg/kg; i.v.), respectively.
Cmaxs of 81.9, 71.2±6.0, 5.56±1.6, and 25.2±5.5 μg/mL for mouse (30 mg/kg; p.o.), rat (7.2 mg/kg; p.o.), dog (2.5 mg/kg; p.o.), and momkey (4.25 mg/kg; p.o.), respectively. |
| | References | [1] Patent: WO2013/102142, 2013, A1. Location in patent: Paragraph 0179
[2] Patent: WO2013/102142, 2013, A1. Location in patent: Paragraph 0178 |
| | Voxelotor Preparation Products And Raw materials |
|